12:00 AM
 | 
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Fetzima levomilnacipran regulatory update

FDA approved an NDA from Forest for Fetzima levomilnacipran to treat major depressive disorder (MDD) in adults. The company said the product...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >